More Company News

Scancell

Surufatinib Phase III SANET-ep study meets primary endpoint at interim analysis and will stop early
14 Jun 2019Read More

Scancell

Preliminary Phase II AML data for bemcentinib in combination with low dose chemotherapy at EHA 2019
14 Jun 2019Read More

Scancell

Completed private placement
14 Jun 2019Read More

Scancell

Update on etigilimab TIGIT partnership
13 Jun 2019Read More

Scancell

Share subscription and issue of equity to Vulpes Life Sciences Fund
13 Jun 2019Read More

Scancell

Phase II elderly AML data for bemcentinib in combination with low dose chemotherapy at ASCO 2019
03 Jun 2019Read More

Scancell

Preliminary clinical and biomarker data from Phase II advanced NSCLC trial with bemcentinib and Keytruda at ASCO 2019
02 Jun 2019Read More

Scancell

Positive early 6-month data for BPS-804 (setrusumab) in OI
30 May 2019Read More

Scancell

Results of EGM
29 May 2019Read More

Scancell

NBS system sold to Jewish General Hospital in Canada
28 May 2019Read More

1 2 3 4 … 22
Return to Scancell
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).